Agnieszka Boesen

Array ( [id] => 11362899 [patent_doc_number] => 20170000879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection' [patent_app_type] => utility [patent_app_number] => 15/212930 [patent_app_country] => US [patent_app_date] => 2016-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 96305 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15212930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114888 [patent_doc_number] => 20160311862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'EPITOPE AND ITS USE OF HEPATITIS B VIRUS SURFACE ANTIGEN' [patent_app_type] => utility [patent_app_number] => 15/207082 [patent_app_country] => US [patent_app_date] => 2016-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7422 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15207082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16443648 [patent_doc_number] => 10835552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Method for preparing linseed polysaccharide having antiviral activity and immunological activity, and use of the linseed polysaccharide [patent_app_type] => utility [patent_app_number] => 15/741530 [patent_app_country] => US [patent_app_date] => 2016-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 5515 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 346 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15741530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14980669 [patent_doc_number] => 10444242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 15/189646 [patent_app_country] => US [patent_app_date] => 2016-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 45841 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15189646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14553719 [patent_doc_number] => 10345311 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 15/189638 [patent_app_country] => US [patent_app_date] => 2016-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 41645 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15189638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12832129 [patent_doc_number] => 20180169215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => Multivalent Enterovirus Vaccine Compositions and Uses Related Thereto [patent_app_type] => utility [patent_app_number] => 15/737239 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11403057 [patent_doc_number] => 20170023595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'METHODS FOR DETECTING AND MEASURING AGGREGATION' [patent_app_type] => utility [patent_app_number] => 15/179769 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 23736 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15179769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15574449 [patent_doc_number] => 10577591 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-03 [patent_title] => Mumps virus as a potential oncolytic agent [patent_app_type] => utility [patent_app_number] => 15/735761 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 42 [patent_no_of_words] => 8470 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15735761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12813232 [patent_doc_number] => 20180162914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => METHODS OF OPTIMIZING NUCLEOTIDE SEQUENCES ENCODING ENGINEERED INFLUENZA PROTEINS [patent_app_type] => utility [patent_app_number] => 15/580192 [patent_app_country] => US [patent_app_date] => 2016-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15580192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12837391 [patent_doc_number] => 20180170970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => VIRAL CHIMERIC PARTICLE OF POTATO VIRUS X AND USE THEREOF FOR IN VITRO DIAGNOSIS OF SJOGREN SYNDROME [patent_app_type] => utility [patent_app_number] => 15/579150 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11335653 [patent_doc_number] => 20160361408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'INFLUENZA VIRUS VACCINES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/158785 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 92856 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15158785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12832150 [patent_doc_number] => 20180169222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => METHODS AND COMPOSITIONS FOR STIMULATING IMMUNE RESPONSE USING POTENT IMMUNOSTIMULATORY RNA MOTIFS [patent_app_type] => utility [patent_app_number] => 15/571096 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12813229 [patent_doc_number] => 20180162913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => METHODS FOR POTENTIATING AN IMMUNE RESPONSE USING DEPOT-FORMING AND NON-DEPOT-FORMING VACCINES [patent_app_type] => utility [patent_app_number] => 15/571003 [patent_app_country] => US [patent_app_date] => 2016-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336558 [patent_doc_number] => 10787503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Antibody-mediated neutralization of Chikungunya virus [patent_app_type] => utility [patent_app_number] => 15/566283 [patent_app_country] => US [patent_app_date] => 2016-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 25 [patent_no_of_words] => 27860 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15566283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12621630 [patent_doc_number] => 20180099040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => HUMANIZED INFLUENZA MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/564897 [patent_app_country] => US [patent_app_date] => 2016-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15564897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11069177 [patent_doc_number] => 20160266142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'METHODS FOR DETECTING AND MEASURING AGGREGATION' [patent_app_type] => utility [patent_app_number] => 15/092499 [patent_app_country] => US [patent_app_date] => 2016-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 23736 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15092499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12681832 [patent_doc_number] => 20180119110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => ASEPTIC PURIFICATION PROCESS FOR VIRUSES [patent_app_type] => utility [patent_app_number] => 15/561094 [patent_app_country] => US [patent_app_date] => 2016-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8998 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18186374 [patent_doc_number] => 11576932 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR) [patent_app_type] => utility [patent_app_number] => 16/089809 [patent_app_country] => US [patent_app_date] => 2016-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 20 [patent_no_of_words] => 18732 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12866317 [patent_doc_number] => 20180180614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => ANTIBODY-MEDIATED NEUTRALIZATION OF EBOLA VIRUSES [patent_app_type] => utility [patent_app_number] => 15/561193 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12238521 [patent_doc_number] => 20180071384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'VACCINES BASED ON HEPATITIS B CORE ANTIGENS' [patent_app_type] => utility [patent_app_number] => 15/560462 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 12169 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560462 [rel_patent_id] =>[rel_patent_doc_number] =>)